A novel oral androgen receptor (AR) inhibitor
Enzalutamide is a specific androgen receptor (AR)inhibitor. It can not only block the binding of androgens to the receptor but also inhibit the translocation of the receptor into the cell nucleus and the binding of the androgen receptor to DNA. Therefore, it is not only an androgen receptor antagonist but also inhibits the androgen signaling pathway.
Indications:
Adult patients with nonmetastatic cachectic-resistant prostate cancer (NM-CRPC) who are at high risk of metastasis.
Treatment of asymptomatic or minimally symptomatic adult patients with metastatic chemorefractory prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and are not receiving chemotherapy.
STRENGTH:
40mg/capsule
Download instructions
Contact us